This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
You do not have access to the full text of this article, the first page of the PDF of this article appears above.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
July 2020
Volume 1, Issue 1
Volume 1, Issue 1
Q&A: Carl June on CAR T-cell Therapy
Jump to section
- Article
- In your TED talk, you say, “Discoveries of this magnitude don't happen overnight.” What went into making T-cell engineering a clinical triumph?
- Why do you think the approach worked better in humans?
- Your focus shifted from HIV to cancer immunotherapy when your first wife was fighting cancer. Did that experience change the way you do research?
- How do you see the role of academia versus industry in innovative therapies?
- Why is translation to the clinic faster for CAR T cells than for standard drugs?
- How many people have lived longer thanks to CAR T-cell therapies?
- Do you expect this trajectory even though CAR T cells are not as easy to make as traditional medicines?
- How can developing countries leapfrog to CAR T-cell therapies?
- Did the COVID-19 pandemic place your research on pause?
- How do your trainees stay productive during this time?
- What do you think will be the next revolution in this field?
- Footnotes
- Info & Metrics
Advertisement